ClinicalTrials.gg
CompletedNCT00318656Updated May 7, 2009Results posted

24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

A Phase 4 interventional study of rosiglitazone-metformin fixed dose combination and metformin + glimepiride in Non-Insulin-Dependent Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-05-07.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
248th of 287
23 · median 100
Started
2005
with 14 others
Phase 4
98 of 293
6 open now
Registered
26th of 293
by date
Lead sponsor
12 of 293
GlaxoSmithKline

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 248th largest by enrollment of the 287 interventional ones that give a count, is one of 15 that started in 2005, is one of 98 in phase 4, and was the 26th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea (glimepiride).

03

Conditions studied

  • Non-Insulin-Dependent Diabetes Mellitus

Keywords

  • type 2 diabetes
  • rosiglitazone
  • metformin
  • glimepiride
  • glycemia
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 40 to 80 years
  • Diagnosis of type 2 diabetes mellitus for at least 6 months
  • (BMI) ≥25kg/m2
  • 7%≥ ≤ 9% at visit 2
  • Treatment with metformin between 1.7g/day and 3g/day for at least 12 weeks prior to visit 1
  • Female subjects must be non-pregnant, , surgically sterile or using effective measures
  • Written

Exclusion criteria

Exclusion Criteria:

  • Use of any oral antidiabetic drug other than metformin within 12 weeks prior to screening
  • Significant to thiazolidinediones and sulfonylureas or compounds with similar chemical structure
  • Subjects who have required the use of insulin for glycaemic control at any time in the past or subject with a history of metabolic acidosis including diabetic ketoacidosis
  • Subjects with ongoing oedema or with a history of oedema in the 12 months prior to visit 1
  • Subjects with a history of severe hypoglycaemia
  • Anemia defined by concentration \<11.0g/dL for males or \<10.0g/dL for females
  • Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels ≥135µmol/L in males and ≥110µmol/L in females
  • Presence of clinically significant hepatic disease (i.e. , AST, total or alkaline phosphatase >2.5 times the reference range)
  • Congestive heart failure ( class I to IV), unstable or severe angina, recent myocardial infarction
  • Subjects with chronic diseases requiring periodic or intermittent treatment with oral or intravenous
  • Female who are lactating, pregnant, or planning to become pregnant
  • Any clinically significant abnormality identified at screening which in the judgement of the investigator makes the subject unsuitable for inclusion in the study (e.g. physical examination, laboratory test, , ...)
  • Use of any agent within 30 days or 5 half-lives (whichever is longer) prior to enrolment in this study
  • Active alcohol, drug or medication abuse within the last 6 months or any condition that would indicate the likelihood of poor subject compliance
  • Subjects not willing to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Interventions

  • Drugrosiglitazone-metformin fixed dose combination
  • Drugmetformin + glimepiride

    Drug pages: Metformin · Glimepiride

    Also known as: rosiglitazone-metformin fixed dose combination

06

What researchers measure

Primary outcomes

  1. Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  2. Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Duration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  2. Episodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  3. Duration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  4. Episodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  5. Duration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  6. Episodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

    Time frame: Baseline and 12 weeks

  7. HbA1c (Glycosylated Hemoglobin)

    Uncontrolled HbA1c\>8.5%. HbA1c and fasting blood glucose taken at hospital

    Time frame: Baseline and 12 weeks

  8. 8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate

    8-Iso Prostaglandin F2α (8-iso PGF2α) excretion rate measured during the 24 hours preceding the CGM system removal. The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time.

    Time frame: Baseline and 12 weeks

  9. Glycaemia According to CGMS (Nocturnal), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time.

    Time frame: Baseline and 12 weeks

  10. Glycaemia According to CGMS (Diurnal), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The diurnal glycemia measured by CGM system will be the average of glycemic values recorded between breakfast time and midnight.

    Time frame: Baseline and 12 weeks

  11. Glycaemia According to CGMS (Dawn), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The glycemia "at dawn" measured by CGM system will be defined as the average of glycemic values recorded between 4 AM and breakfast time.

    Time frame: Baseline and 12 weeks

  12. Glycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

    Time frame: Baseline and 12 weeks

  13. Glycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

    Time frame: Baseline and 12 weeks

  14. Glycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL

    Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

    Time frame: Baseline and 12 weeks

  15. Glycaemia According to CGMS (MAGE), mg/dL

    Calculation of the Mean amplitude of glycemic excursion (MAGE) was obtained by measuring the arithmetic mean of the major glucose concentration increases or decreases on days 2 and 3 of glycaemic profile and then averaging results on the two days.

    Time frame: Baseline and 12 weeks

07

Results

Posted Mar 18, 2009

Participant flow

Participant flow — Overall Study
MilestoneAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Started1211
Completed129
Not completed02
Withdrew: Took avandamet instead of glim/met01
Withdrew: Did not receive any treatment01

Outcome measures

PrimaryDuration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Hours
Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
HoursAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline17.31 ± 6.2517.53 ± 6.84
12 weeks15.30 ± 6.1010.83 ± 6.06
Statistical analysis
  • Avandamet® (Rosiglitazone/Metformin) vs Glimepiride/Metformin · ANCOVA · p = 0.064 · Mean difference (net): 5.02 · 95% CI -0.32 to 10.36Mean Difference =(Rosiglitazone + Met) - (Glimepiride+Met)
PrimaryEpisodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Episodes
Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
EpisodesAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline3.91 ± 2.034.05 ± 2.51
12 weeks5.36 ± 2.675.90 ± 3.01
Statistical analysis
  • Avandamet® (Rosiglitazone/Metformin) vs Glimepiride/Metformin · ANCOVA · p = 0.923 (P value von elteren (adjusted on sex)) · Mean difference (net): -0.26 · 95% CI -3.37 to 2.85Mean Difference =(Rosiglitazone + Met) - (Glimepiride+Met)
SecondaryDuration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Hours
Duration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
HoursAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline11.28 ± 8.6712.35 ± 7.13
12 weeks6.39 ± 5.304.23 ± 5.32
SecondaryEpisodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Episodes
Episodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
EpisodesAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline4.00 ± 1.953.55 ± 1.34
12 weeks5.00 ± 2.982.95 ± 2.83
SecondaryDuration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Hours
Duration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
HoursAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline0.85 ± 1.540.24 ± 0.45
12 weeks0.64 ± 1.970.41 ± 0.80
SecondaryEpisodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Episodes
Episodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
EpisodesAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline0.64 ± 0.870.30 ± 0.63
12 weeks0.50 ± 1.360.80 ± 1.60
SecondaryDuration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Hours
Duration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
HoursAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline0.51 ± 1.060 ± 0
12 weeks0.14 ± 0.470.08 ± 0.26
SecondaryEpisodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Episodes
Episodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
EpisodesAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline0.50 ± 1.020 ± 0
12 weeks0.14 ± 0.450.1 ± 0.32
SecondaryHbA1c (Glycosylated Hemoglobin)

Uncontrolled HbA1c\>8.5%. HbA1c and fasting blood glucose taken at hospital

Time frame:
Baseline and 12 weeks
Reported as:
Mean · Percentage
HbA1c (Glycosylated Hemoglobin)
PercentageAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline7.8 ± 0.657.7 ± 0.50
12 weeks7.4 ± 0.627.1 ± 0.79
Secondary8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate

8-Iso Prostaglandin F2α (8-iso PGF2α) excretion rate measured during the 24 hours preceding the CGM system removal. The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pg/mL
8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate
pg/mLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline361.9 ± 207.53325.1 ± 148.2
12 weeks373.5 ± 180.15320.4 ± 84.74
SecondaryGlycaemia According to CGMS (Nocturnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Nocturnal), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline148.4 ± 42.94140.4 ± 30.18
12 weeks130.2 ± 21.97126.3 ± 21.76
SecondaryGlycaemia According to CGMS (Diurnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The diurnal glycemia measured by CGM system will be the average of glycemic values recorded between breakfast time and midnight.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Diurnal), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline162.1 ± 43.1158.7 ± 27.40
12 weeks139.1 ± 15.23130.13 ± 21.17
SecondaryGlycaemia According to CGMS (Dawn), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The glycemia "at dawn" measured by CGM system will be defined as the average of glycemic values recorded between 4 AM and breakfast time.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Dawn), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline145.0 ± 37.23138.6 ± 23.44
12 weeks130.6 ± 21.31124.7 ± 20.26
SecondaryGlycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline1428.2 ± 971.31293.1 ± 636.3
12 weeks891.4 ± 342.4717.7 ± 460.6
SecondaryGlycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline522.8 ± 271.6443.0 ± 157.9
12 weeks356.9 ± 138.4362.7 ± 177.3
SecondaryGlycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline905.6 ± 728.2850.1 ± 601.2
12 weeks534.5 ± 307.5355.0 ± 338.2
SecondaryGlycaemia According to CGMS (MAGE), mg/dL

Calculation of the Mean amplitude of glycemic excursion (MAGE) was obtained by measuring the arithmetic mean of the major glucose concentration increases or decreases on days 2 and 3 of glycaemic profile and then averaging results on the two days.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Glycaemia According to CGMS (MAGE), mg/dL
mg/dLAvandamet® (Rosiglitazone/Metformin)Glimepiride/Metformin
Baseline75.1 ± 22.561.6 ± 13.7
12 weeks44.2 ± 18.350.8 ± 16.4

Baseline characteristics

Age Continuous
Age Continuous(years)Avandamet® (Rosiglitazone/Metformin)Glimepiride/MetforminTotal
Mean59 ± 10.362.2 ± 6.660.5 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Avandamet® (Rosiglitazone/Metformin)Glimepiride/MetforminTotal
Female527
Male6814
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Avandamet® (Rosiglitazone/Metformin)Glimepiride/MetforminTotal
Mean32.2 ± 6.630.1 ± 4.831.2 ± 5.8
HbA1c
HbA1c(percentage)Avandamet® (Rosiglitazone/Metformin)Glimepiride/MetforminTotal
Mean7.8 ± 0.517.8 ± 0.527.8 ± 0.50
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Monnier L, Colette C, Comenducci A, Vallee D, Dejager S. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther. 2012 Oct;14(10):943-50. doi: 10.1089/dia.2012.0045. Epub 2012 Jul 9. PubMed 22775317 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2006
First posted
Apr 27, 2006
Start
Nov 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Mar 18, 2009
Last update
May 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00318656
Lead sponsor
GlaxoSmithKline
First posted
Apr 27, 2006
Start date
Nov 2005
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Mar 18, 2009
Last update
May 7, 2009

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Glimepiride

Start the discussion